Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden

INTRODUCTION: Adjuvant trastuzumab is a standard of care in the treatment of Human Epidermal growth factor Receptor 2 (HER2) positive early breast cancer (eBC). Initially trastuzumab could only be administered intravenously (IV), however since 2013, a subcutaneous (SC) formulation with comparable ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedayati, Elham, Fracheboud, Lionel, Srikant, Vaidyanathan, Greber, David, Wallberg, Susanne, Linder Stragliotto, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361452/
https://www.ncbi.nlm.nih.gov/pubmed/30716137
http://dx.doi.org/10.1371/journal.pone.0211783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361452/
https://www.ncbi.nlm.nih.gov/pubmed/30716137
http://dx.doi.org/10.1371/journal.pone.0211783

Ejemplares similares